Research site

Dermedic Jacek Zdybski

Poland ul. H. Sienkiewicza 65/14/II, 27-400 Ostrowiec Swietokrzyski, Poland

1 trial recruiting
Neurodermatitis · Vitiligo · Hidradenitis
Adult patients

About Specializations

Dermedic Jacek Zdybski in Ostrowiec Swietokrzyski, Poland specialises in clinical trials of conditions such as Neurodermatitis, Vitiligo, Hidradenitis, and other specialisations. This site conducts important research.

Main research areas of the site

Skin and Connective Tissue Diseases

The research program at Dermedic Jacek Zdybski concentrates on skin and connective tissue diseases, with particular attention to hidradenitis suppurativa, prurigo nodularis, and vitiligo. Ongoing studies are designed to evaluate the long‑term safety of innovative therapies and to enhance treatment strategies for chronic dermatologic conditions.

Long‑term safety assessment of novel biologics
Evaluation of targeted JAK inhibitors
Patient‑reported outcome measures in chronic skin disorders

Dermedic Jacek Zdybski collaborates with local investigators to advance dermatology research, offering patients access to cutting‑edge therapeutic options in Ostrowiec Świętokrzyski, Poland.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

ul. H. Sienkiewicza 65/14/II27-400 Ostrowiec SwietokrzyskiPoland

Open in maps ↗

Recruiting now: 1 trial
Conditions studied: 3

More sites in Ostrowiec Swietokrzyski Poland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

2 clinical trials

Vitiligo+2

Recruiting

InvestigationalNo placebo

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Povorcitinib
Sponsor:Incyte Corp.

Contact Research Centre

Neurodermatitis

Not recruiting

InvestigationalNo placebo

Study on the Long-Term Safety and Effectiveness of Nemolizumab for Patients with Prurigo Nodularis

InvestigationalNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Nemolizumab
Sponsor:Galderma S.A.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites